Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
Key appointment bringing 30 years of drug discovery and development expertise as the Company continues to build a portfolio of first-in-class targets Leadership experience across multiple product-driven research organisations Instrumental in progressing numerous programmes through to clinic Oxford, UK, 13 November 2023 – Nucleome Therapeutics (‘Nucleome' or ‘the Company'), a biotechnology company decoding the dark matter of the human genome for translational medicine, today announces the appointment of Dr Stephen Harrison as Chief Scientific Officer, effective immediately. Dr Harrison has three decades of experience in the biotechnology sector, with leadership experience at product-driven research organisations at all stages, from target identification to new drug registration and clinical development in multiple therapeutic areas including immunotherapeutics, oncology, rare diseases and pain management. Prior to joining Nucleome, Dr Harrison held executive leadership posit
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions [Seeking Alpha]Seeking Alpha
- Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $100.00 to $118.00. They now have a "buy" rating on the stock.MarketBeat
- Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 12/23/25 - Form 4
- 12/23/25 - Form 4
- 12/16/25 - Form 8-K
- NKTR's page on the SEC website